12-YEAR OUTCOMES FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER

2005281 citationsJournal Article

Authors

Louis Potters · South Nassau Communities Hospital

C. Morgenstern · Mercy Medical Center

Emil Calugaru · Memorial Sloan Kettering Cancer Center

Paul Fearn · Memorial Sloan Kettering Cancer Center

Anup Jassal · Memorial Sloan Kettering Cancer Center

Joseph Presser · South Nassau Communities Hospital

E.E. Mullen

Abstract

PPB offers acceptable 12-year BFR in patients who present with clinically localized prostate cancer. Implant dosimetry continues as an important predictor for BFR, while the addition of adjuvant therapies such as hormones and external radiation are insignificant. In patients who experience biochemical failure it appears that PSA doubling time is an important predictor of survival.

Topics & Keywords

Prostate Cancer Diagnosis and Treatment Prostate Cancer Treatment and Research Advanced Radiotherapy Techniques

UN Sustainable Development Goals

Peace, Justice and strong institutions

Publication Details

Published in: The Journal of Urology

Volume 173, Issue 5, pp. 1562-1566

DOI: 10.1097/01.ju.0000154633.73092.8e

Field-Weighted Citation Impact: 18.76